Program
LY3971297
A development code. Also written as “LY3971297 IV”.
Its studies are mostly in Heart Failure · Obesity, led by Eli Lilly.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 21 open or running | phase 1since Nov 20, 2023 | Nov 20, 2023 | Nov 2027phase 1 · NCT07547540 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 20, 2023First study: phase 1 study in ObesityFirst studyNCT06148272 · 200 enrolled · United States, Japan, Singapore
- Apr 17, 2026Phase 1 study in Heart FailureNCT07547540 · 90 planned · United States, Japan, Moldova and more
Ahead
- Nov 2027Primary completion: phase 1 study in Heart FailureNCT07547540
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07547540Heart Failure · United States, Japan, Moldova and more | 1 | Recruiting | Nov 2027 | 90 |
| NCT06148272Obesity · United States, Japan, Singapore | 1 | Completed | Aug 18, 2026 | 200 |
How it is read
Names in the registry
- “LY3971297”, 3 entries
- “LY3971297 IV”, 1 entry
Codes read as this program: LY3971297.
Conditions, from the studies’ own filings
- Heart Failure, 1 study
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.